Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia
Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia
复制标题
DOI：
10.1001/archderm.141.3.368
复制
发表时间：
2005-03-01
影响因子：
--
通讯作者：
Mills, G
中科院分区：
文献类型：
--
作者：
Ayirookuzhi, SJ;Ramshesh, P;Mills, G
背景：甲磺酸伊马替尼已成为目前治疗慢性粒细胞白血病（CML）的主要化疗药物之一。虽然这种药物的皮肤反应已经记录之前，这是第一次，甜综合征已报告与其use.Observations：我们报告的情况下，甜综合征继发于伊马替尼治疗慢性粒细胞白血病。在2个单独的场合，一个53岁的非裔美国妇女与慢性粒细胞白血病发展嗜中性皮肤病与Sweet综合征化疗后与imatinib.Conclusion：更大的认识伊马替尼的不良反应和表征其皮肤的不良反应将导致改善监测和治疗这些不良反应。
Background: Imatinib mesylate has become one of the main chemotherapeutic agents currently used to treat patients with chronic myeloid leukemia (CML). Although cutaneous reactions to this drug have been documented before, this is the first time that Sweet syndrome has been reported with its use.Observations: We report a case of Sweet syndrome secondary to the administration of imatinib to treat CML. On 2 separate occasions, a 53-year-old African American woman with CML developed neutrophilic dermatosis consistent with Sweet syndrome after chemotherapy with imatinib.Conclusion: Greater awareness of the adverse effects of imatinib and the characterization of its cutaneous adverse effects will lead to improved surveillance for and treatment of those adverse effects.